BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 23631607)

  • 1. Nateglinide and acarbose are comparably effective reducers of postprandial glycemic excursions in chinese antihyperglycemic agent-naive subjects with type 2 diabetes.
    Zhou J; Li H; Zhang X; Peng Y; Mo Y; Bao Y; Jia W
    Diabetes Technol Ther; 2013 Jun; 15(6):481-8. PubMed ID: 23631607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential therapeutic effects of nateglinide and acarbose on fasting and postprandial lipid profiles: a randomized trial.
    Zhou J; Deng Z; Lu J; Li H; Zhang X; Peng Y; Mo Y; Bao Y; Jia W
    Diabetes Technol Ther; 2015 Apr; 17(4):229-34. PubMed ID: 25781235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nateglinide and acarbose for postprandial glucose control after optimizing fasting glucose with insulin glargine in patients with type 2 diabetes.
    Kim MK; Suk JH; Kwon MJ; Chung HS; Yoon CS; Jun HJ; Ko JH; Kim TK; Lee SH; Oh MK; Rhee BD; Park JH
    Diabetes Res Clin Pract; 2011 Jun; 92(3):322-8. PubMed ID: 21376417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved post-prandial ghrelin response by nateglinide or acarbose therapy contributes to glucose stability in Type 2 diabetic patients.
    Zheng F; Yin X; Lu W; Zhou J; Yuan H; Li H
    J Endocrinol Invest; 2013; 36(7):489-96. PubMed ID: 23324437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a new insulinotropic agent by using an innovative technology: efficacy and safety of nateglinide determined by continuous glucose monitoring.
    Abrahamian H; Francesconi M; Loiskandl A; Dzien A; Prager R; Weitgasser R
    Diabetes Technol Ther; 2004 Feb; 6(1):31-7. PubMed ID: 15000767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of nateglinide and acarbose on glycemic excursions in standardized carbohydrate and mixed-meal tests in drug-naïve type 2 diabetic patients.
    Li H; Xu W; Liu J; Chen A; Liao Z; Li Y
    Biomed Rep; 2013 Nov; 1(6):913-917. PubMed ID: 24649052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beneficial metabolic effects of nateglinide versus acarbose in patients with newly-diagnosed type 2 diabetes.
    Gao HW; Xie C; Wang HN; Lin YJ; Hong TP
    Acta Pharmacol Sin; 2007 Apr; 28(4):534-9. PubMed ID: 17376293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.
    Horton ES; Clinkingbeard C; Gatlin M; Foley J; Mallows S; Shen S
    Diabetes Care; 2000 Nov; 23(11):1660-5. PubMed ID: 11092289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control.
    Fonseca V; Grunberger G; Gupta S; Shen S; Foley JE
    Diabetes Care; 2003 Jun; 26(6):1685-90. PubMed ID: 12766094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes.
    Hollander PA; Schwartz SL; Gatlin MR; Haas SJ; Zheng H; Foley JE; Dunning BE
    Diabetes Care; 2001 Jun; 24(6):983-8. PubMed ID: 11375357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin.
    Hirschberg Y; Karara AH; Pietri AO; McLeod JF
    Diabetes Care; 2000 Mar; 23(3):349-53. PubMed ID: 10868864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166).
    Gribble FM; Manley SE; Levy JC
    Diabetes Care; 2001 Jul; 24(7):1221-5. PubMed ID: 11423506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy: A Placebo-Controlled Trial.
    Derosa G; Franzetti I; Querci F; D'Angelo A; Maffioli P
    Pharmacotherapy; 2015 Nov; 35(11):983-90. PubMed ID: 26598090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia.
    Saloranta C; Hershon K; Ball M; Dickinson S; Holmes D
    J Clin Endocrinol Metab; 2002 Sep; 87(9):4171-6. PubMed ID: 12213867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone.
    Ristic S; Collober-Maugeais C; Pecher E; Cressier F
    Diabet Med; 2006 Jul; 23(7):757-62. PubMed ID: 16842480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.
    Raskin P; Klaff L; McGill J; South SA; Hollander P; Khutoryansky N; Hale PM;
    Diabetes Care; 2003 Jul; 26(7):2063-8. PubMed ID: 12832314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycemic variability in insulin treated type 2 diabetes with well-controlled hemoglobin A1c and its response to further treatment with acarbose.
    Su JB; Wang XQ; Chen JF; Wu G; Jin Y
    Chin Med J (Engl); 2011 Jan; 124(1):144-7. PubMed ID: 21362322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study.
    Rosenstock J; Hassman DR; Madder RD; Brazinsky SA; Farrell J; Khutoryansky N; Hale PM;
    Diabetes Care; 2004 Jun; 27(6):1265-70. PubMed ID: 15161773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population.
    Saloranta C; Guitard C; Pecher E; De Pablos-Velasco P; Lahti K; Brunel P; Groop L
    Diabetes Care; 2002 Dec; 25(12):2141-6. PubMed ID: 12453951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.